Inactive Instrument

Press Releases Biosyent Inc. Toronto S.E.

Equities

BioSyent In-Licenses Endocrinology Product for Canada	Jun. 12	GL
BioSyent Releases Financial Results for Q1 2024	May. 16	GL
BioSyent Declares Second Quarter 2024 Dividend	May. 16	GL
BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024	May. 09	GL
BioSyent to Attend Planet MicroCap Showcase	Apr. 23	GL
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement	Apr. 15	GL
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference	Apr. 10	GL
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year	Apr. 03	GL
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year	Apr. 03	AQ
BioSyent to Present at LD Micro New York Investor Conference	Apr. 01	GL
BioSyent Announces Grant of Restricted Share Units	Mar. 27	GL
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023	Mar. 13	GL
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023	Mar. 13	AQ
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024	Mar. 06	GL
BioSyent Named to 2024 TSX Venture 50	Feb. 21	GL
BioSyent Named to 2024 TSX Venture 50	Feb. 21	AQ
BioSyent Declares First Quarter 2024 Dividend	Feb. 06	GL
BioSyent Declares First Quarter 2024 Dividend	Feb. 06	AQ
BioSyent Announces Renewal of Normal Course Issuer Bid	Dec. 13	GL
BioSyent Announces the Availability of Gelclair® in Canada	Nov. 20	GL

No results for this search